Microcyn: a Novel Super-oxidized Water with Neutral PH and Disinfectant Activity
Overview
Infectious Diseases
Authors
Affiliations
A new super-oxidized water (SOW) product, Microcyn, was tested for in vitro antimicrobial and antiviral activities. The effectiveness of this neutral-pH SOW at killing Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Salmonella typhi and Candida albicans in pure culture was evaluated. One millilitre (approximately 10(8)colony-forming units/mL) of each micro-organism was subjected to 9 mL Microcyn or sterile water at room temperature for 30s. Under these conditions, a log(10) reduction factor of 8 in the level of all pathogens occurred in the treatment samples. In addition, results of tests with three batches of Microcyn exposed to Bacillus atrophaeus spores for 5 min demonstrated complete inactivation of the spores within 2-3 min (log(10) reduction factor >4). The effectiveness of Microcyn in reducing human immunodeficiency virus-1 (HIV-1) on hard surfaces (glass) was also evaluated in compliance with Environmental Protection Agency requirements for virucidal claims. After exposure of the tested surfaces to Microcyn for 5 min without agitation, there was a log(10) reduction factor >3 in the viral load as measured by both cytopathic effect and antigen p24 of HIV-1 production in MT-2 cultures. Microcyn activity against adenoviral vector type 5 was also analysed under simulated laboratory in-use conditions with viral suspensions. In order to increase the sensitivity of the test, the fluorescent light emitted by AdGFP-infected cells was measured with the use of a flow cytometer. A log(10) reduction factor >3 in the viral load was achieved after a 5-min exposure to Microcyn under these strict conditions. These results show that Microcyn exerts a wide antimicrobial spectrum with major advantages over acidic SOWs, including neutral pH, lower free active chlorine (51-85 ppm) and long shelf life (1 year).
Activity of Antiseptics Against and Its Adaptation Potential.
Karpinski T, Korbecka-Paczkowska M, Stasiewicz M, Mrozikiewicz A, Wlodkowic D, Cielecka-Piontek J Antibiotics (Basel). 2025; 14(1).
PMID: 39858316 PMC: 11760470. DOI: 10.3390/antibiotics14010030.
Gonzalez-Cantu C, Torres-Munoz A, Urrutia-Baca V, Sanchez-Garcia G, De la Garza-Ramos M Heliyon. 2023; 8(12):e12291.
PMID: 36590522 PMC: 9798187. DOI: 10.1016/j.heliyon.2022.e12291.
Cardenas A, Campos-Bijit V, DI Francesco F, Schwarz F, Cafferata E, Vernal R BMC Oral Health. 2022; 22(1):579.
PMID: 36494635 PMC: 9733258. DOI: 10.1186/s12903-022-02528-0.
The role of hypochlorous acid in the management of eye infections: a case series.
Bertone C, Mollicone A, Russo S, Sasso P, Fasciani R, Riccardi C Drugs Context. 2022; 11.
PMID: 35865000 PMC: 9267159. DOI: 10.7573/dic.2022-3-10.
Garcia-Valdivia M, Quinones-Vico M, Ortega-Llamas L, Fernandez-Gonzalez A, Ubago-Rodriguez A, Sanabria-de la Torre R Biomedicines. 2022; 10(6).
PMID: 35740473 PMC: 9220084. DOI: 10.3390/biomedicines10061453.